BCL2 and autoimmune disease: After in vitro stimulation with CpG for 6 days, plasmablasts were more viable after treatment with Bcl-2 inhibitors for 24 h compared to naïve or memory B cells of healthy controls and autoimmune diseases (Fig. 3).